Clinical Trial Update: Chronic Inflammation, Plasma Proteins Signature, Survival Outcomes and Clinical Response, in Patients Receiving Bevacizumab Combined With Oxaliplatin-based Chemotherapy (Bev/OX) or Bevacizumab Combined With Irinotecan-based Chemotherapy (Bev/IRI)

View source ↗

Summary

This clinical trial update reports results from a completed study evaluating bevacizumab combined with oxaliplatin-based chemotherapy versus bevacizumab combine…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Bevacizumab (bevacizumab)
• Irinotecan (Irinotecan)
• OXALIPLATIN (Oxaliplatin)

Snippet

Sponsor: Second Affiliated Hospital of Nanchang University | Conditions: Colorectal Cancer, Resistance | Status: COMPLETED